These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Identify glioma recurrence and treatment effects with triple-tracer PET/CT. Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015 [TBL] [Abstract][Full Text] [Related]
24. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663 [TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Interim 18F-DOPA and 18F-FDG PET/CT Findings in Stage 3-4 Pediatric Neuroblastoma. Ko KY; Yen RF; Ko CL; Chou SW; Chang HH; Yang YL; Jou ST; Hsu WM; Lu MY Clin Nucl Med; 2022 Jan; 47(1):21-25. PubMed ID: 34874346 [TBL] [Abstract][Full Text] [Related]
26. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Kidd EA; Dehdashti F; Siegel BA; Grigsby PW Radiother Oncol; 2010 Jun; 95(3):288-91. PubMed ID: 20231040 [TBL] [Abstract][Full Text] [Related]
27. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma. Wartski M; Jehanno N; Michon J; de Labriolle-Vaylet C; Montravers F Clin Nucl Med; 2015 Dec; 40(12):969-70. PubMed ID: 26544903 [TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365 [TBL] [Abstract][Full Text] [Related]
29. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108 [TBL] [Abstract][Full Text] [Related]
30. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors. Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292 [TBL] [Abstract][Full Text] [Related]
32. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495 [TBL] [Abstract][Full Text] [Related]
33. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620 [TBL] [Abstract][Full Text] [Related]
34. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387 [TBL] [Abstract][Full Text] [Related]
35. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888 [TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781 [TBL] [Abstract][Full Text] [Related]
38. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility. Basu S; Li G; Bural G; Alavi A Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692 [TBL] [Abstract][Full Text] [Related]
39. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363 [TBL] [Abstract][Full Text] [Related]
40. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]